clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2024-102-2-101-108clinmed-757Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESЭффективность препарата марибавир по данным клинических исследованийEfficacy of the drug maribavir according to clinical studieshttps://orcid.org/0009-0004-4524-3142ДрачукЕ. С.DrachukE. S.

Елизавета Сергеевна Драчук, ординатор

Ростов-на-Дону

Elizaveta S. Drachuk, resident

Rostov-On-Don

vkomissiya@inbox.ruhttps://orcid.org/0000-0002-5952-4787ГубановаА. А.GubanovaA. A.

Анастасия Андреевна Губанова, студентка 6-го курса

Ростов-на-Дону

Anastasiya A. Gubanova, six year student

Rostov-On-Don

https://orcid.org/0000-0002-9903-0431ХаидбаевИ.HaidbayevI.

Ислам Хаидбаев, ординатор

Йошкар-Ола

Islam Haidbayev, resident

Yoshkar-Ola

https://orcid.org/0000-0003-4070-0813БурмистроваВ. Н.BurmistrovaV. N.

Валерия Николаевна Бурмистрова, аспирант

Москва

Valeriya N. Burmistrova, graduate student

Moscow

https://orcid.org/0000-0002-9352-1176АндреяноваК. А.AndreyanovaK. A.

Ксения Андреевна Андреянова, студентка 6-го курса

Ростов-на-Дону

Kseniya A. Andreyanova, six year student

Rostov-On-Don

https://orcid.org/0000-0001-8069-2737ХертекЮ. А.HertekYu. A.

Юнас Аржанович Хертек, ординатор

Санкт-Петербург

Yunas A. Hertek, resident

Saint Petersburg

https://orcid.org/0000-0002-1754-0762ТучинаВ. Е.TuchinaV. E.

Валерия Евгеньевна Тучина, ординатор

Санкт-Петербург

Valeriya E. Tuchina, resident

Saint Petersburg

https://orcid.org/0000-0003-1980-9005КузьминаС. В.KuzminaS. V.

София Вячеславовна Кузьмина, студентка 6-го курса

Йошкар-Ола

Sofia V. Kuzmina, six year student

Yoshkar-Ola

https://orcid.org/0000-0001-7325-0471КуликоваО. В.KulikovaO. V.

Олеся Валерьевна Куликова, студентка 6-го курса

Йошкар-Ола

Olesya V. Kulikova, six year student

Yoshkar-Ola

https://orcid.org/0000-0003-2122-986XБородинаА. Р.BorodinaA. R.

Александра Романовна Бородина, студентка 6-го курса

Москва

Alexandra R. Borodina, six year student

Moscow

https://orcid.org/0000-0002-3661-2418ПетраковА. А.PetrakovA. A.

Андрей Александрович Петраков, студент 6-го курса

Москва

Andrey A. Petrakov, six year student

Moscow

https://orcid.org/0009-0000-6634-8964ОмС. М.OmS. M.

София Максимовна Ом, студентка 6-го курса

Санкт-Петербург

Sofia M. Om, six year student

Saint Petersburg

omsofia99@mail.ruhttps://orcid.org/0009-0007-4187-0503БабюкВ. В.BabyukV, V.

Валерия Владимировна Бабюк, студентка 6-го курса

Ростов-на-Дону

Valeriya V. Babyuk, six year student

Rostov-On-Don

ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава РоссииРоссияRostov State Medical University of the Ministry of Healthcare of RussiaRussian FederationФГБОУ ВО «Марийский государственный университет»РоссияMari State UniversityRussian FederationФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава РоссииРоссияA.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of RussiaRussian FederationФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. И.П. Павлова» Минздрава РоссииРоссияAcademician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of RussiaRussian Federation5ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава РоссииРоссияNorth-Western State Medical University named after I.I. Mechnikоv of the Ministry of Healthcare of RussiaRussian Federation2024070520241022101108Copyright © Драчук Е.С., Губанова А.А., Хаидбаев И., Бурмистрова В.Н., Андреянова К.А., Хертек Ю.А., Тучина В.Е., Кузьмина С.В., Куликова О.В., Бородина А.Р., Петраков А.А., Ом С.М., Бабюк В.В., 20242024Драчук Е.С., Губанова А.А., Хаидбаев И., Бурмистрова В.Н., Андреянова К.А., Хертек Ю.А., Тучина В.Е., Кузьмина С.В., Куликова О.В., Бородина А.Р., Петраков А.А., Ом С.М., Бабюк В.В.Drachuk E.S., Gubanova A.A., Haidbayev I., Burmistrova V.N., Andreyanova K.A., Hertek Y.A., Tuchina V.E., Kuzmina S.V., Kulikova O.V., Borodina A.R., Petrakov A.A., Om S.M., Babyuk V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/757

   Современная медицина испытывает высокую потребность в новых препаратах для профилактики и лечения цитомегаловирусной (ЦМВ) инфекции. В данном обзоре рассматривается марибавир — пероральный противовирусный препарат с селективной мультимодальной анти-ЦМВ -активностью для лечения взрослых и детей с посттрансплантационной ЦМВ-инфекцией, резистентной к традиционной анти-ЦМВ-терапии. Несмотря на множество клинических испытаний препарата марибавир, результаты его эффективности неоднозначны. Наряду с успешными исследованиями, результаты которых говорят о высокой эффективности обозреваемого препарата, имеются данные о статистически безуспешных исследованиях.

   Целью настоящего обзора является рассмотрение механизма действия препарата марибавир на цитомегаловирусную инфекцию, механизмов вирусной чувствительности и кросс-резистентности, а также обобщение результатов клинических исследованиях препарата.

   Modern medicine has a high demand for new drugs for the prevention and treatment of cytomegalovirus (CMV) infection. This review discusses maribavir — an oral antiviral drug with selective multimodal anti-CMV activity for the treatment of adults and children with post-transplant CMV infection resistant to traditional anti-CMV therapy. Despite numerous clinical trials of maribavir, the results of its effi cacy are ambiguous. Alongside successful studies indicating high effi cacy of the drug under review, there are data from statistically unsuccessful studies.

   The aim of this review is to examine the mechanism of its action on cytomegalovirus infection, viral sensitivity and cross-resistance mechanisms, as well as to summarize the results of clinical trials of the drug.

марибавирцитомегаловируспротивовирусная терапияклинические исследованияпротеинкиназа UL97maribavircytomegalovirusantiviral therapyclinical trialsprotein kinase UL97Исследование не имело спонсорской поддержкиThe study had no sponsorshipReferencesHaidar G., Boeckh M., Singh N. Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence. J. Infect. Dis. 2020;221(1):S23–S31. DOI: 10.1093/infdis/jiz454Haidar G., Boeckh M., Singh N. Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence. J. Infect. Dis. 2020;221(1):S23–S31. DOI: 10.1093/infdis/jiz454Teira P., Battiwalla M., Ramanathan M. et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427–38. DOI: 10.1182/blood-2015-11-679639Teira P., Battiwalla M., Ramanathan M. et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427–38. DOI: 10.1182/blood-2015-11-679639Khawaja F., Batista M.V., El Haddad L., Chemaly R.F. Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation: diagnosis and management. Curr. Opin. Infect. Dis. 2019;32(6):565–574. DOI: 10.1097/QCO.0000000000000607Khawaja F., Batista M.V., El Haddad L., Chemaly R.F. Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation: diagnosis and management. Curr. Opin. Infect. Dis. 2019;32(6):565–574. DOI: 10.1097/QCO.0000000000000607Mehta Steinke S.A., Alfares M., Valsamakis A. et al. Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection. Transpl. Infect. Dis. 2021;23(3):e13521. DOI: 10.1111/tid.13521Mehta Steinke S.A., Alfares M., Valsamakis A. et al. Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection. Transpl. Infect. Dis. 2021;23(3):e13521. DOI: 10.1111/tid.13521Biron K.K., Harvey R.J., Chamberlain S.C. et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 2002;46(8):2365–72. DOI: 10.1128/AAC.46.8.2365-2372.2002Biron K.K., Harvey R.J., Chamberlain S.C. et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 2002;46(8):2365–72. DOI: 10.1128/AAC.46.8.2365-2372.2002Drew W.L., Miner R.C., Marousek G.I., Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J. Clin. Virol. 2006;37(2):124–7. DOI: 10.1016/j.jcv.2006.07.010Drew W.L., Miner R.C., Marousek G.I., Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J. Clin. Virol. 2006;37(2):124–7. DOI: 10.1016/j.jcv.2006.07.010Avery R.K., Alain S., Alexander B.D. et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin. Infect. Dis. 2022;75(4):690–701. DOI: 10.1093/cid/ciab988Avery R.K., Alain S., Alexander B.D. et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin. Infect. Dis. 2022;75(4):690–701. DOI: 10.1093/cid/ciab988Chou S., Wechel L.C., Marousek G.I. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J. Infect. Dis. 2007;196(1):91–4. DOI: 10.1086/518514Chou S., Wechel L.C., Marousek G.I. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J. Infect. Dis. 2007;196(1):91–4. DOI: 10.1086/518514Hamirally S., Kamil J.P., Ndassa-Colday Y.M. et al. Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. PLoS Pathog. 2009;5(1):e1000275. DOI: 10.1371/journal.ppat.1000275Hamirally S., Kamil J.P., Ndassa-Colday Y.M. et al. Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. PLoS Pathog. 2009;5(1):e1000275. DOI: 10.1371/journal.ppat.1000275Chou S., Hakki M., Villano S. Eff ects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. Antiviral. Res. 2012;95(2):88–92. DOI: 10.1016/j.antiviral.2012.05.013Chou S., Hakki M., Villano S. Eff ects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. Antiviral. Res. 2012;95(2):88–92. DOI: 10.1016/j.antiviral.2012.05.013Chou S., Song K., Wu J. et al. Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection. J. Infect. Dis. 2022;226(4):576–584. DOI: 10.1093/infdis/jiaa462Chou S., Song K., Wu J. et al. Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection. J. Infect. Dis. 2022;226(4):576–584. DOI: 10.1093/infdis/jiaa462Chou S., Wu J., Song K., Bo T. Novel UL97 drug resistance mutations identifi ed at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. Antiviral. Res. 2019;172:104616. DOI: 10.1016/j.antiviral.2019.104616Chou S., Wu J., Song K., Bo T. Novel UL97 drug resistance mutations identifi ed at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. Antiviral. Res. 2019;172:104616. DOI: 10.1016/j.antiviral.2019.104616Chou S. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrob. Agents Chemother. 2009;53(1):81–5. DOI: 10.1128/AAC.01177-08Chou S. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrob. Agents Chemother. 2009;53(1):81–5. DOI: 10.1128/AAC.01177-08Chou S., Marousek G.I., Senters A.E. et al. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J. Virol. 2004;78(13):7124–30. DOI: 10.1128/JVI.78.13.7124-7130.2004Chou S., Marousek G.I., Senters A.E. et al. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J. Virol. 2004;78(13):7124–30. DOI: 10.1128/JVI.78.13.7124-7130.2004Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 2008;18(4):233–46. DOI: 10.1002/rmv.574Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 2008;18(4):233–46. DOI: 10.1002/rmv.574Reitsma J.M., Savaryn J.P., Faust K. et al. Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest. Cell Host Microbe. 2011;9(2):103–14. DOI: 10.1016/j.chom.2011.01.006Reitsma J.M., Savaryn J.P., Faust K. et al. Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest. Cell Host Microbe. 2011;9(2):103–14. DOI: 10.1016/j.chom.2011.01.006Kamil J.P., Coen D.M. HATs on for drug resistance. Cell Host Microbe. 2011;9(2):85–7. DOI: 10.1016/j.chom.2011.02.001Kamil J.P., Coen D.M. HATs on for drug resistance. Cell Host Microbe. 2011;9(2):85–7. DOI: 10.1016/j.chom.2011.02.001Chou S., Marousek G.I. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J. Virol. 2008;82(1):246–53. DOI: 10.1128/JVI.01787-07Chou S., Marousek G.I. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J. Virol. 2008;82(1):246–53. DOI: 10.1128/JVI.01787-07Chou S., Marousek G.I. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob. Agents Chemother. 2006;50(10):3470–2. DOI: 10.1128/AAC.00577-06Chou S., Marousek G.I. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob. Agents Chemother. 2006;50(10):3470–2. DOI: 10.1128/AAC.00577-06Selleseth D.W., Talarico C.L., Miller T. et al. Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. Antimicrob. Agents Chemother. 2003;47(4):1468–71. DOI: 10.1128/AAC.47.4.1468-1471.2003Selleseth D.W., Talarico C.L., Miller T. et al. Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. Antimicrob. Agents Chemother. 2003;47(4):1468–71. DOI: 10.1128/AAC.47.4.1468-1471.2003Evers D.L., Komazin G., Shin D. et al. Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus. Antiviral. Res. 2002;56(1):61–72. DOI: 10.1016/s0166-3542(02)00094-3Evers D.L., Komazin G., Shin D. et al. Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus. Antiviral. Res. 2002;56(1):61–72. DOI: 10.1016/s0166-3542(02)00094-3Chou S., Ercolani R.J., Derakhchan K. Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. Antiviral. Res. 2018;157:128–133. DOI: 10.1016/j.antiviral.2018.07.013Chou S., Ercolani R.J., Derakhchan K. Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. Antiviral. Res. 2018;157:128–133. DOI: 10.1016/j.antiviral.2018.07.013Wang L.H., Peck R.W., Yin Y. et al. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodefi ciency virus-infected subjects. Antimicrob. Agents Chemother. 2003;47(4):1334–42. DOI: 10.1128/AAC.47.4.1334-1342.2003Wang L.H., Peck R.W., Yin Y. et al. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodefi ciency virus-infected subjects. Antimicrob. Agents Chemother. 2003;47(4):1334–42. DOI: 10.1128/AAC.47.4.1334-1342.2003Lalezari J.P., Aberg J.A., Wang L.H. et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodefi ciency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 2002;46(9):2969–76. DOI: 10.1128/AAC.46.9.2969-2976.2002Lalezari J.P., Aberg J.A., Wang L.H. et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodefi ciency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 2002;46(9):2969–76. DOI: 10.1128/AAC.46.9.2969-2976.2002Canas S.M., Johnson J., Gelone S. et al. Bioavailability of maribavir whole tablet is unaff ected by crushing the tablet. Transplantation and Cellular Therapy. 2009;15(2):109. DOI: 10.1016/j.bbmt.2008.12.335Canas S.M., Johnson J., Gelone S. et al. Bioavailability of maribavir whole tablet is unaff ected by crushing the tablet. Transplantation and Cellular Therapy. 2009;15(2):109. DOI: 10.1016/j.bbmt.2008.12.335Song I., Ilic K., Sun K., Martin P. Clinical pharmacology of maribavir (SHP620): a comprehensive overview. Biol. Blood Marrow Transplant. 2019;25:S342. DOI: 10.1016/j.bbmt.2018.12.554Song I., Ilic K., Sun K., Martin P. Clinical pharmacology of maribavir (SHP620): a comprehensive overview. Biol. Blood Marrow Transplant. 2019;25:S342. DOI: 10.1016/j.bbmt.2018.12.554Ma J.D., Nafziger A.N., Villano S.A. et al. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob. Agents Chemother. 2006;50(4):1130–5. DOI: 10.1128/AAC.50.4.1130-1135.2006Ma J.D., Nafziger A.N., Villano S.A. et al. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob. Agents Chemother. 2006;50(4):1130–5. DOI: 10.1128/AAC.50.4.1130-1135.2006Marty F.M., Boeckh M. Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed? Curr. Opin. Virol. 2011;1(6):555–62. DOI: 10.1016/j.coviro.2011.10.011Marty F.M., Boeckh M. Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed? Curr. Opin. Virol. 2011;1(6):555–62. DOI: 10.1016/j.coviro.2011.10.011Williams S.L., Hartline C.B., Kushner N.L. et al. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 2003;47(7):2186–92. DOI: 10.1128/AAC.47.7.2186-2192.2003Williams S.L., Hartline C.B., Kushner N.L. et al. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 2003;47(7):2186–92. DOI: 10.1128/AAC.47.7.2186-2192.2003Koszalka G.W., Johnson N.W., Good S.S. et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 2002;46(8):2373–80. DOI: 10.1128/AAC.46.8.2373-2380.2002Koszalka G.W., Johnson N.W., Good S.S. et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 2002;46(8):2373–80. DOI: 10.1128/AAC.46.8.2373-2380.2002Swan S.K., Smith W.B., Marbury T.C. et al. Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment. J. Clin. Pharmacol. 2007;47(2):209–17. DOI: 10.1177/0091270006296765Swan S.K., Smith W.B., Marbury T.C. et al. Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment. J. Clin. Pharmacol. 2007;47(2):209–17. DOI: 10.1177/0091270006296765Maffini E., Giaccone L., Festuccia M. et al. Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation. Expert Rev. Hematol. 2016;9(6):585–96. DOI: 10.1080/17474086.2016.1174571Maffini E., Giaccone L., Festuccia M. et al. Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation. Expert Rev. Hematol. 2016;9(6):585–96. DOI: 10.1080/17474086.2016.1174571Pescovitz M.D., Bloom R., Pirsch J. et al. A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. Am. J. Transplant. 2009;9(10):2324–30. DOI: 10.1111/j.1600-6143.2009.02768.xPescovitz M.D., Bloom R., Pirsch J. et al. A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. Am. J. Transplant. 2009;9(10):2324–30. DOI: 10.1111/j.1600-6143.2009.02768.xHalpern-Cohen V., Blumberg E.A. New perspectives on antimicrobial agents: maribavir. Antimicrob. Agents Chemother. 2022;66(9):e0240521. DOI: 10.1128/aac.02405-21Halpern-Cohen V., Blumberg E.A. New perspectives on antimicrobial agents: maribavir. Antimicrob. Agents Chemother. 2022;66(9):e0240521. DOI: 10.1128/aac.02405-21Winston D.J., Young J.A., Pullarkat V. et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111(11):5403–10. DOI: 10.1182/blood-2007-11-121558Winston D.J., Young J.A., Pullarkat V. et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111(11):5403–10. DOI: 10.1182/blood-2007-11-121558Marty F.M., Ljungman P., Papanicolaou G.A. et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect. Dis. 2011;11(4):284–92. DOI: 10.1016/S1473-3099(11)70024-XMarty F.M., Ljungman P., Papanicolaou G.A. et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect. Dis. 2011;11(4):284–92. DOI: 10.1016/S1473-3099(11)70024-XWinston D.J., Saliba F., Blumberg E. et al. Effi cacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am. J. Transplant. 2012;12(11):3021–30. DOI: 10.1111/j.1600-6143.2012.04231.xWinston D.J., Saliba F., Blumberg E. et al. Effi cacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am. J. Transplant. 2012;12(11):3021–30. DOI: 10.1111/j.1600-6143.2012.04231.xMaertens J., Cordonnier C., Jaksch P. et al. Maribavir for preemptive treatment of cytomegalovirus reactivation. N. Engl. J. Med. 2019;381(12):1136–1147. DOI: 10.1056/NEJMoa1714656Maertens J., Cordonnier C., Jaksch P. et al. Maribavir for preemptive treatment of cytomegalovirus reactivation. N. Engl. J. Med. 2019;381(12):1136–1147. DOI: 10.1056/NEJMoa1714656Alain S., Revest M., Veyer D. et al. Maribavir use in practice for cytomegalovirus infection in French transplantation centers. Transplant. Proc. 2013;45(4):1603–7. DOI: 10.1016/j.transproceed.2013.01.082Alain S., Revest M., Veyer D. et al. Maribavir use in practice for cytomegalovirus infection in French transplantation centers. Transplant. Proc. 2013;45(4):1603–7. DOI: 10.1016/j.transproceed.2013.01.082Avery R.K., Marty F.M., Strasfeld L. et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl. Infect. Dis. 2010;12(6):489–96. DOI: 10.1111/j.1399-3062.2010.00550.xAvery R.K., Marty F.M., Strasfeld L. et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl. Infect. Dis. 2010;12(6):489–96. DOI: 10.1111/j.1399-3062.2010.00550.xPapanicolaou G.A., Silveira F.P., Langston A.A. et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. Clin. Infect. Dis. 2019;68(8):1255–1264. DOI: 10.1093/cid/ciy706Papanicolaou G.A., Silveira F.P., Langston A.A. et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. Clin. Infect. Dis. 2019;68(8):1255–1264. DOI: 10.1093/cid/ciy706ClinicalTrials.gov: USA. [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/NCT05137717 (data access: 30. 05. 2023).ClinicalTrials.gov: USA. [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/NCT05137717 (data access: 30. 05. 2023).Kotton C.N., Kumar D., Caliendo A.M. et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018;102(6):900–931. DOI: 10.1097/TP.0000000000002191Kotton C.N., Kumar D., Caliendo A.M. et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018;102(6):900–931. DOI: 10.1097/TP.0000000000002191

The authors declare that there are no conflicts of interest present.